Novo Nordisk announced a €432 million ($506 million) investment in its Athlone, Ireland facility to expand production capacity for its newly launched Wegovy pill.
The expansion will add significant oral GLP‑1 manufacturing capacity, with construction already underway and expected to be completed gradually from the end of 2027 through 2028. The project is projected to create up to 500 construction jobs and will build on the existing workforce of about 260 employees at the Athlone site.
The Wegovy pill, launched in the United States on January 5, 2026, has seen rapid uptake, with more than 240,000 Americans taking the medication since launch and 170,000 by January 23. The strong launch is a key driver for the investment, as Novo Nordisk seeks to meet growing global demand outside the United States.
Novo Nordisk’s investment reinforces its strategy to strengthen the supply chain for its flagship obesity drug and positions the company to capture a larger share of the expanding global GLP‑1 market, projected to reach $126 billion by 2029. The move also counters competition from Eli Lilly’s tirzepatide‑based products, such as Zepbound, and supports Novo Nordisk’s broader focus on oral formulations to broaden patient access.
Financially, Novo Nordisk reported 10% sales growth and 6% operating profit growth in 2025, but issued a cautious 2026 outlook that forecasts a 5%–13% decline in sales and operating profit at constant exchange rates due to pricing pressures, intensifying competition, and currency headwinds. Gross margin fell to 81% in 2025 from 84.7% in 2024, underscoring the importance of efficient manufacturing and cost management in the Athlone expansion.
Management highlighted the strategic importance of the investment. Kasper Bødker Mejlvang said, "With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will enable us to meet both current and future global demand outside the US." CEO Mike Doustdar added, "The launch of Wegovy in pill form in early January had been one of the most successful pharmaceutical debuts ever, with more than 240,000 Americans taking it already." He also noted, "If we were about to throw in the towel, we would not be investing in factories in Ireland."
The Athlone expansion reflects Novo Nordisk’s commitment to Ireland and its broader strategy to invest in growth areas while navigating headwinds in pricing and competition. The investment is expected to support the company’s long‑term growth trajectory in the obesity and diabetes markets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.